Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
PGDx, the defendant in the liquid biopsy IP case, has alleged that Guardant's CEO should have been named as an inventor on patents but was purposefully left off.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
The mass spec-based assay can detect viral proteins eight days after the onset of symptoms, compared to four to five days with PCR tests, its developers said.
Dubbed "Sherlock," the new technology has demonstrated potential in detecting viruses and bacteria as well as human SNPs and mutations in cell-free DNA.
The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
PerkinElmer may be nearing an FDA submission for a panel based on technology from the University of Washington, amid a push for state-mandated screening programs.
Research using the T2Plex instrument has detected a new conformation of red blood cells indicating a tight clot, which could be used as a biomarker.
Agendia, which makes the MammaPrint test, called the report "disappointing" but thinks it still has a shot at landing wider reimbursement in Germany.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.
The planned instrument will help provide spatial information on both protein and RNA in tumor samples and will be powered by nCounter technology.